Intermittent intravenous cyclophosphamide therapy for lupus nephritis
References (24)
- et al.
Development of hypogammaglobulinemia in a patient with systemic lupus erythematosus
Am J Med
(1986) - et al.
Gonadal function in women treated with cyclophosphamide for childhood nephrotic syndrome: a long-term follow-up study
Fertil Steril
(1986) - et al.
Malignancy following treatment of rheumatoid arthritis with cyclophosphamide: long-term case controlled follow-up study
Am J Med
(1987) - Lehman TJA, McCurdy DK, Bernstein BH, King KK, Hanson V. Systemic lupus erythematosus in the first decade of life....
- et al.
Systemic lupus erythematosus in the younger patient: survival studies
J Rheumatol
(1980) - et al.
Therapy of lupus nephritis: controlled trial of prednisone, and cytotoxic drugs
N Engl J Med
(1986) - et al.
Effect of treatment on the evolution of renal abnormalities in lupus nephritis
N Engl J Med
(1984) - et al.
Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus
N Engl J Med
(1988) - et al.
The 1982 revised criteria for the classification of systemic lupus erythematosus
Arthritis Rheum
(1982) - et al.
Cyclophosphamide in lupus nephritis: a controlled trial
Ann Intern Med
(1971)
A double-blind controlled trial comparing cyclophosphamide, azathioprine, and placebo, in the treatment of lupus glomerulonephritis
Arthritis Rheum
Cyclophosphamide or azathioprine in lupus glomerulonephritis: a controlled trial—results at 28 months
Ann Intern Med
Cited by (106)
Systemic Lupus Erythematosus
2015, Textbook of Pediatric RheumatologySystemic lupus erythematosus: Treatment-renal involvement
2015, Rheumatology: Sixth EditionBiomarkers and Updates on Pediatrics Lupus Nephritis
2013, Rheumatic Disease Clinics of North AmericaCitation Excerpt :Based on small studies, children and adolescents have a response to MMF and cyclophosphamide similar to that of adults with LN.134 Whether MMF is as effective in children as it is in adults135 or whether cyclophosphamide might have a better risk/benefit profile in children than in adults owing to lower frequency of clinically relevant ovarian injury and lower risk of nonadherence is not supported by high-level scientific evidence.129 In addition, the pediatric correlate of the “Euro Lupus Regimen” for the dosing of intravenous cyclophosphamide has not been developed or systematically studied.14
Treatment of Systemic Lupus Erythematosus
2012, Kelley's Textbook of Rheumatology: Volume 1-2, Ninth EditionChapter 5 Systemic Lupus Erythematosus: Etiology, Pathogenesis, Clinical Manifestations, and Management
2007, Handbook of Systemic Autoimmune DiseasesCitation Excerpt :Albumin infusions and diuretics are often needed for severe nephrotic syndrome. CYC is a cytotoxic agent that has been shown to improve the course of LN in children by cross-linking DNA strands thus interfering with cell-division (Lehman et al., 1989b;Lehman and Onel, 2000). CYC is considered the standard of care for treatment of Class IV LN, and has been well studied in children.
Clinical practice guidance for childhood-onset systemic lupus erythematosus - secondary publication
2022, Modern Rheumatology